

SUBJECT INDEX

A

ABCB1

drug resistance gene,
327-28

ABCG1, 20-21

ABCG2, 381-99

ABCG2/BCRP, 381-99
cancer and, 391-92, 395
dimerization, 390
drug resistance and,
391-92
function of, 389-94
modulation of function,
394-97
significance of variants,
397-98
stem cells and, 387-88
structure of, 383, 389-91
subcellular localization of,
389-91
substrates, 393-97
tissue distribution of,
386-87

Accessory proteins

for G proteins, 151-73

Activator protein-1 (AP-1)

redox sensitive, 221

Activators of G protein

signaling (AGS)
proteins, 151-53,
155-60, 163-65,
167-73

Acute lymphoblastic

leukemia (ALL),
317-40

Acute myeloid leukemia

(AML), 317-40
chemoresistance and,
391-92

Adenosine diphosphate

(ADP)

platelet aggregation and,
287-88

platelet responsiveness to,
284-85

platelets and, 277-64

Adenosine triphosphate

(ATP)
platelets and, 279-82
P2X receptor and, 278
thrombus formation and,
279

Adenosine triphosphate

(ATP)-binding cassette
(ABC), 327

Adenosine triphosphate

(ATP)-binding cassette
(ABC) transporter
ABCG2/BCRP, 381-99

Adenosine triphosphate

(ATP)-binding cassette
(ABC) transporter A1
(ABCA1) gene
atherosclerosis and, 7
liver X receptor (LXR) and,
7, 13, 15, 19, 20, 25-26

Adenoviral infections

CYP regulation and, 126

Adipose tissue

inflammation within, 4

ADP

See Adenosine diphosphate
(ADP)

Age

flavin-containing
monooxygenase (FMO)
and, 83-85

Amino acid

ABCG2 and, 397

Androgen receptor

ABCG2 and, 385

Angiogenesis

platelets and, 277

Angiotensin-converting
enzyme inhibition
(ACEI), 261-62

Angiotensin receptor blockers
(ARB), 261

Anticancer strategy

ABCG2 and, 395-97

Antiobesity drugs

CB1 antagonists as,
106-7

Antioxidants

CYP activity and, 128

Antiplatelet compounds

P2Y₁ receptor as target of,
288-90

Antiplatelet drugs, 291

Antithrombotic drugs, 279

platelet P2 receptors and,
285-86

P2Y₁₂ receptor and,
285-86

Antitumor activity

of proteasome inhibitors,
205

Antitumor agents

proteasome inhibitors as,
193-94

Antitumor effects

of proteasome inhibitors,
195-97

Arterial intima

atherosclerosis and, 2

Aryl hydrocarbon receptor

(AHR), 42
CYPs and, 44, 46
humanized mice, 52-53

Ascorbic acid

antioxidant, 260

Aspirin, 291

clopidogrel with, 290

- COX inhibitor, 279
- Atherogenesis
 metabolic syndrome and, 3–4
- Atherosclerosis, 278
 development of, 1–3
 endothelial nitric oxide synthase (eNOS) and, 256–57
 risk factors and, 3–4
- Atherosclerotic plaque
 rupture
 platelets and, 277
- ATP
 See Adenosine triphosphate (ATP)
- B**
- Bcl-2 family members
 proteasome
 inhibitor-mediated apoptosis and, 196
- BCRP/ABCG2
 cloning, 382–83
- Bilirubin, 425
- Biliverdin, 425
- Bioinformatics, 321
- Blood platelets
 P2 receptors and, 277–92
- Bortezomib, 192, 195–97
 anthracycline and, 200
 antitumor activity, 193–94
 cancer treatments with, 198
 clinical studies, 189, 192, 200–6
 combination therapies with, 198
 hematologic malignancies and, 202
 myeloma cell lines and, 198
 myeloma patients and, 201
 pharmacology of, 200–1
- Breast cancer
 chemoresistance and, 198
- Breast cancer-resistance protein, 328
- C**
- c-Jun N-terminal kinase (JNK) pathway
 proteasome
 inhibitor-mediated apoptosis and, 196
- C5a receptor, 501–2
- Calcium (Ca)
 nitric oxide synthase (NOS) activity and, 239–40
- Calcium channel blockers (CCB), 261, 262
- Calmodulin, 239–40
- Camptothecin, 398
 ABCG2 and, 395, 396
- Cancer
 ABCG2 and, 391–92, 395
 anticancer drug resistance, 337–38
 flavin-containing monooxygenase (FMO) and, 88
 platelets and, 277
 proteases and, 301–11
 resistance to chemotherapy, 321
 therapy
 proteasome inhibitors in, 189–206
 treatment(s), 197–99
 individualization and optimization of, 340
- Cannabinoid
 therapeutics, 101–13
- Cannabinoid receptor(s), 101–13
- CB1, 101–9, 112
 antagonists, 106–9, 111–13
- CB2, 101–3, 106, 109–11
 agonists, 109–11, 113
- Cannabis
 extracts, 105
- Carbon monoxide (CO), 420–22, 428, 429, 431, 432
- antiproliferative effects of, 425–26
- apoptosis and, 422–23
- caveolae and, 430–32
- caveolin-1 and, 430–32
- cell cycle and, 423–24
- as a cellular signaling molecule, 411–32
- chronic inhalation of, 430
- circadian clock and, 418–20
- effect on macrophages, 426–28
- effect on T cells, 428–29
- HO-derived, 411, 413
- neointimal formation and, 426
- neuronal PAS domain protein-2 (NPAS-2) and, 418–20
- p38 MAPK and, 420–22, 428, 429, 431, 432
- receptors
 hemoproteins as, 416–20
- sensitivity to hypoxia and, 430
- soluble guanylyl cyclase (sGC) and, 417–20, 429
- Carboplatin, 198
- Carcinogens
 cytochrome P450 enzymes and, 41
- Carcinomas
 ABCG2 and, 392
- CATCH22 syndrome, 464, 465
- Cation channels
 nitric oxide (NO) and, 247–48
- Caveolae
 carbon monoxide (CO) and, 430–32
- caveolae-residing proteins, 427–28
- endothelial nitric oxide synthase (eNOS) and, 238–39

- signaling domain and, 426
 Caveolin-1, 430-32
 CDC34
 multiple myeloma and, 195
 Cell cycle
 carbon monoxide (CO)
 and, 423-24
 lactacystin arrests, 192-93
 p38 MAPK and, 423-24
 Cellular detoxification
 ABCG2 and, 384
 Cellular signaling pathways
 CYP regulation and,
 128-29
 Center for Proteolytic
 Pathways, 302
 Chemokine receptor
 transmembrane (TM)
 receptors and, 500-1
 Chemoresistance
 proteasome inhibitors and,
 197-200
 Chemosensitivity
 genomics and, 321
 Chemotherapy
 antileukemic, 321-29
 leukemia and, 318
 Childhood acute leukemia,
 317-40
 Cholesterol
 atherosclerosis and, 3, 5-6
 drug therapy for, 6-7
 macrophage/foam cell and,
 7-8
 microdomains and, 431
 Chronic lymphocytic
 leukemia (CLL)
 proteasome inhibitors and,
 194
 Circadian clock
 carbon monoxide (CO)
 and, 418-20
 Cisplatin, 198
 Cks1b
 myeloma patients and,
 194-95
 Clinical drug trials
 pharmacogenetic studies
 and, 340
 Clinical trials
 of thienopyridines,
 285-86
 Clopidogrel, 285
 with aspirin, 290
 clinical trials, 285-86
 resistance, 286-87
 Clozapine
 inflammation and, 127
 Colon carcinoma cells
 cell growth signaling in,
 227-28
 Congenital deficiencies
 P2 receptors and, 284
 Constitutive androstane
 receptor (CAR), 42, 44,
 46-47
 humanized mice, 54
 Constitutively active receptor
 (CAR)
 ABCG2 and, 384
 Coronary artery disease
 (CAD)
 atherosclerosis, 1
 statins and, 2-3
 vitamin C treatment and,
 260
 CPT-11
 bortezomib with, 198
 Craving
 CB1 antagonists and,
 108-9
 CREST study, 202
 Crohn's disease
 CYP activity and, 126
 Cyclooxygenase (COX)
 thrombus formation and,
 279
 Cyclophosphamide, 198
 CYP enzymes
 diabetes and, 88-89
 downregulated in
 inflammation, 125-27
 drug metabolism by, 43
 flavin-containing
 monooxygenase (FMO)
 and, 80-81
 inflammation and, 123-35,
 139-40
 mechanisms of regulation,
 127-33
 nitric oxide (NO) and,
 132-33
 regulation of, 125-32
 role in inflammation
 response, 133-35
 CYP3A4, 44, 45, 47
 CYP3A4-humanized mice,
 50-51
 CYP2D6, 42, 44, 45, 47
 CYPD6-humanized mice
 cytochrome P450 and,
 47-50
 CYP2E1, 45
 CYP2E1-humanized mice,
 51-52
 Cysteine (Cys)/cysteine
 (CySS), 217
 redox, 225-28
 Cytochrome P450 (CYP450),
 65
 antileukemic agents and,
 322-23
 inflammatory responses
 and, 134-35
 xenobiotic receptor
 humanized mice and,
 41-56
 xenobiotics and, 43-44
 Cytokines
 roles and sources of,
 127-28
 Cytoplasmic redox couples
 transcription factor
 regulation and, 221-23

D

- Dephosphorylation
 endothelial nitric oxide
 synthase (eNOS) and, 255
 Detoxification
 cellular, 384

- Dexamethasone
bortezomib and, 202-5
- Diabetes
atherosclerosis and, 4
flavin-containing
monooxygenase (FMO)
and, 88-89
- Diet
flavin-containing
monooxygenase (FMO)
and, 82-83
- Diflomotecan, 398
- Dihydrofolate reductase
(DHFR)
methotrexate (MTX)
resistance and, 332
- Diseases
flavin-containing
monooxygenase (FMO)
gene family and, 86-90
- Dose-limiting toxicities
(DLTs)
bortezomib and, 201
- Doxorubicin, 323
bortezomib and, 204
myeloma cell lines and,
198
- Dronabinol, 105
- Drug development
flavin-containing
monooxygenase (FMO)
and, 81-82
pharmacogenomics and,
340
- Drug-drug interactions
adverse, 82-83
- Drug metabolism
cytochrome P450s and,
43-44
infection and, 126-27
species differences in, 47
- Drug metabolizing enzymes
(DMEs)
inflammation and, 123-40
regulation of, 125-37
- Drug reactions, 43
- Drug resistance
ABCG2 and, 381-99
anticancer, 337-38
gene expression associated
with, 338-39
membrane transporters
and, 327-29
proteasome inhibitors and,
205
- Drug therapy
atherosclerosis and, 3
macrophages as target for,
5-8
- Dyslipidemia
endothelial nitric oxide
synthase (eNOS) and,
256-57
- E**
- 11S proteasome activator,
191
- Embryogenesis
rexinoid receptors (RXRs)
and, 459-60
- Embryonic stem (EX) cells
ABCG2 and, 388
- Endocannabinoid(s), 102-4
neuronal plasticity and,
104-5
signaling system, 102
transport inhibitors, 112
- Endoplasmic reticulum (ER)
apoptotic pathways and,
197
- Endothelial cells
antithrombotic surface of,
278
- Endothelial nitric oxide
synthase(s)(eNOS),
235-64, 431, 432
dephosphorylation and,
255
estrogen and, 252-54, 258
extracellular regulation of,
249-55
G protein-coupled
receptors and, 250-51
high-density lipoprotein
(HDL) and, 257-58
hormones and, 253-54
hypoxia and, 258-59
insulin and, 253
low-density lipoprotein
(LDL) and, 256-57
lysophosphatidic acid
(LPA) and, 251-52
oxidative stress and,
259-60
pathophysiologic states
affecting, 256-60
receptor-independent
pathways of activation,
254
sphingosine 1-phosphate
(S1P) and, 251-52
thrombin and, 254
vascular endothelial growth
factor (VEGF) and,
252-53
- Endothelium
nitrosylation and cation
channels in, 247-48
- eNOS
See Endothelial nitric
oxide synthase(s) (eNOS)
- Enzymes
drug metabolizing enzymes
(DMEs)
inflammation and,
123-40
phase I, 41-43
antileukemic agents and,
322-24
phase 2, 41-42, 135, 139
- Epinephrine
binding process, 497-500
- Epoxomicin, 192, 193
- Estrogen
endothelial nitric oxide
synthase (eNOS) and,
252-54, 258
- Estrogen response element
(ERE)
ABCG2 and, 385-86
- Eye morphogenesis

neural crest and, 465-66
Ezetimibe, 3

F

Familial adenomatous polyposis (FAP), 88
Fatty acid amino hydrolase (FAAH), 104, 111-12
Fatty streaks
 atherosclerotic lesion, 1-2
Fibrates, 1, 12, 13, 15-16
Fireflies, 263
Flavin-containing monooxygenase (FMO), 65-90
 age and, 83-85
 cancer and, 88
 catalytic mechanism, 80-81
 diabetes and, 88-89
 diet and, 82-83
 drug development and, 81-82
 gender and, 85-86
 gene organization, 68-69
 genetic variation, 69-71
 hemochromatosis and, 88
 human, 65-90
 hypertension and, 86-87
 interindividual differences of, 71-74
 nicotine and, 89-90
 nomenclature, 66-67
 posttranscriptional regulation and, 71
 protein structure of, 80-81
 regulation, 67-68
 smoking and, 89-90
 species differences, 67-68
 splicing variants, 79-80
 transcriptional regulation and, 70-71
 X-ray crystallography of, 90
Flavin-containing monooxygenase (FMO)

 single nucleotide polymorphisms (SNPs) and 4, 78-79
 Flavin-containing monooxygenase (FMO)
 1, 74-75
 Flavin-containing monooxygenase (FMO)
 2, 75-76
 Flavin-containing monooxygenase (FMO)
 3
 disease and, 86-90
 interindividual variability in human, 71-74
 rare mutations, 77-78
 single nucleotide polymorphisms (SNPs) and, 76-78
 Flavin-containing monooxygenase (FMO)
 5, 78-79
 Flavin-containing monooxygenase (FMO)
 6
 pseudogene, 66
 Flavin monooxygenase (FMO), 123, 135
 Flow conditions
 thrombus formation and, 282-83
 Flow systems
 platelet function studies with, 282-83

G

G protein(s)
 accessory proteins for, 151-73
 altered interactions of subunits, 171-72
 guanine nucleotide exchange factors (GEFs) and, 155-63, 165-67
G protein-coupled receptor(s) (GPCR), 151-55, 164-66, 168, 170-73

 endothelial nitric oxide synthase (eNOS) and, 250-51
 ligands for, 250-52
 phospholipase C (PLC) and, 363, 366, 372
 See also Seven transmembrane receptors (7TM)
G protein-regulated isozymes
 novel structural features of, 362-64
GAP-43, 155, 156, 164, 167, 172
Gefitinib
 ABCG2 and, 395-97
Gemcitabine, 198
Gender
 flavin-containing monooxygenase (FMO) and, 85-86
Gene(s)
 expression
 drug resistance and, 337-39
 profiling, 319-20
 treatment response in leukemia and, 334-39
 flavin-containing monooxygenase (FMO), 66, 67, 90
 age and, 84
 organization of, 68-69
 pharmacogenomics and, 317-40
Genetic polymorphisms
 antileukemic chemotherapy and, 321-29
Genetic variation
 flavin-containing monooxygenase (FMO) and, 69-71
Genotyping methods, 319
Ghrelin receptor family
 toggle switch activation and, 502
Glitazones, 16, 21

- Glucocorticoid receptor (NR3C1), 333–34
- Glucocorticosteroids
acute lymphoblastic leukemia (ALL) and, 333–34
- Glutathione (GSH), 222–23, 229
glutathione (GSH)/glutathione disulfide (GSSG), 217, 225–26
nuclear compartmentation of, 217–18
- Glutathione S-transferase(s) (GST), 123, 135–36
chemotherapeutic agents and, 324–25
- Green fluorescent proteins (GFPs), 218–20, 228
- GTPase activity
accessory proteins and, 153, 172
- GTPases activating protein (GAP)
phospholipase C (PLC) and, 362
- Guanine nucleotide dissociation inhibitors (GDIs), 155–60, 167–68
- Guanine nucleotide exchange factor(s) (GEFs), 371
G proteins and, 155–63, 165–67, 172
Ras, 364, 370
signal input for, 167, 173
GW7647, 14–15
- H**
- Haplotypes, 319
- Heat shock proteins (HSPs)
proteasome inhibitors and, 199–200, 205
- Hematologic malignancies
bortezomib studies and, 204, 206
- Heme oxygenase (HO), 411
HO-1, 412
antagonistic induction of, 416
immunity and, 428–29
macrophages and, 426, 428
as a protective gene, 425
synergistic induction of, 414–16
transcriptional regulation of, 414–16
vascular smooth muscle cells and, 425–26
- Hemochromatosis
flavin-containing monooxygenase (FMO) and, 88
- Hemoproteins
as carbon monoxide receptors, 416–20
- Hemostasis, 277, 278
- Hepatic transporters
regulation of, 137–39
- Hepatocyte nuclear factors (HNFs)
inflammation and, 130
- Heterodimers
RXR/RAR, 451–53, 462–64, 466, 467, 469, 470
- High-density lipoprotein(s) (HDL)
atherosclerosis and, 2–3
endothelial nitric oxide synthase (eNOS) and, 257–58
peroxisome proliferator-activated receptor- α (PPAR- α) and, 14
peroxisome proliferator-activated receptor- δ (PPAR- δ) and, 23
- Hormones
endothelial nitric oxide synthase (eNOS) and, 253–54
flavin-containing monooxygenase (FMO) activity and, 70–71
- HSP-72
proteasome inhibitors and, 199–200
- HSP-90
proteasome inhibitors and, 199–200
- Hu/Mu Protein Chip
proteases and, 303
- Human flavin-containing monooxygenase (FMO), 65–90
- Hydrogen sulfide (H₂S), 411
- Hypertension
flavin-containing monooxygenase (FMO) and, 86–87
- Hypoxia
endothelial nitric oxide synthase (eNOS) and, 258–59
- Hypoxia-inducible factor 1 (HIF-1)
ABCG2 and, 385, 391
- Hypoxia-inducible transcription factor (HIF)
ABCG2 and, 388
- Hypoxia response elements (HRE)
ABCG2 and, 385
- I**
- Imaging
of tumor proteolysis, 301–11
- Imatinib
ABCG2 and, 395–96
- Immunity
carbon monoxide (CO) and, 426–29
- Infection

- drug metabolism and, 126–27
- Inflammation**
- CYPs downregulated in, 125–27
- drug disposition in, 123–40
- nitrotyrosine and, 249
- p38 MAPK and, 426–28
- phase II enzymes and, 135, 139
- See also Inflammatory response
- Inflammatory bowel movement (IBD)**
- CYP activity and, 126
- Inflammatory response**
- role of CYPs in, 133–35
- See also Inflammation
- Insulin**
- endothelial nitric oxide synthase (eNOS) and, 253
- See also Insulin resistance (IR); Insulin sensitivity; Insulin-sensitizing drugs
- Insulin resistance (IR)**
- atherosclerosis and, 4
- Insulin sensitivity, 16–18, 24
- Insulin-sensitizing drugs, 16
- Irinotecan, 396–98
- Isozymes**
- phospholipase C, 355–73
- K**
- Kinase inhibitors**
- acute lymphoblastic leukemia (ALL) and, 334
- Koshland induced fit model**
- for ligand binding, 504–6
- L**
- Lactacystin**, 192–93
- Leukemia**
- acute
- pharmacogenomics of, 317–40
- treatment response in, 334–39
- chronic lymphocytic leukemia (CLL), 194
- outcome prediction, 334–36
- Philadelphia
- chromosome-positive acute lymphoblastic leukemia (ALL), 334
- Lipopolysaccharide (LPS)**
- drug metabolizing enzymes (DMEs) in rats treated with, 125–26, 128–32, 134–37
- hepatic transport systems in rodents treated with, 137–39
- Liver X receptor (LXR)**
- ATP binding cassette transporter A1 (ABCA1) gene and, 7, 13, 15, 19, 20, 25–26
- Low-density lipoproteins (LDL)**
- atherosclerosis and, 1–3, 5, 6
- drug therapy for
- atherosclerosis and, 5–7
- endothelial nitric oxide synthase (eNOS) and, 256–57
- nitric oxide (NO) synthesis and, 256
- oxidation, 12, 14
- statins and, 261
- torcetrapib and, 2
- Lymphoma**
- bortezomib and, 202, 203, 205
- Lysophosphatidic acid (LPA)**
- endothelial nitric oxide synthase (eNOS) and, 251–52
- Lysophosphatidylcholine (LPC)**
- endothelial nitric oxide synthase (eNOS) and, 256–57
- M**
- Macrophage(s)**
- atherogenesis and, 5–8
- atherosclerosis and, 1–2
- carbon monoxide (CO) and, 426–28
- foam cell formation, 15
- gene expression in, 18
- peroxisome proliferator-activated receptors (PPARs) and, 1–27
- Major histocompatibility complex (MHC) class I proteasome**, 190
- MAPK**
- See Mitogen-activated protein kinase (MAPK)
- Matrix metalloproteinase inhibitors (MMPIs)**, 301, 302
- Matrix metalloproteinases (MMPs)**
- cancer and, 301–2
- Maximum tolerated dose (MTD)**
- bortezomib and, 201, 202
- Melphalan**
- myeloma and, 198, 205
- Membrane transporters**
- drug resistance and, 327–29
- Mesectodermal derivatives**
- retinoic acid receptors (RARs) and, 456, 458–59
- Metabolic syndrome**
- atherogenesis and, 3–4
- defined, 4
- Metabolism**
- xenobiotic receptors and, 44, 46–47
- Metal centers**
- nitric oxide (NO) reactivity with, 241–44
- Metal ion site(s)**
- transmembrane (TM)

- receptors and, 489–90, 500–1
- Methotrexate (MTX)
acute lymphoblastic leukemia (ALL) and, 331–33
- 5,10-Methylenetetrahydrofolate reductase (MTHFR)
methotrexate (MTX) toxicity and, 333
- MG-132
treatment of myeloma cells with, 197
- Mitochondria
interaction of nitric oxide (NO) with metal centers in, 243
redox states in, 223–24
- Mitochondrial nitric oxide synthase (NOS), 243–44
- Mitochondrial redox, 215–29
redox sensitive green fluorescent proteins (roGFP) and, 225
- Mitogen-activated protein kinase (MAPK)
carbon monoxide (CO) and, 411, 420–22, 432
See also P38
mitogen-activated protein kinase (MAPK)
- Mitogen-activated protein kinase (MAPK)
phosphatase (MKP)-1, 200, 205
- Mitoxantrone
ABCG2 and, 383, 394
myeloma cell lines and, 198
- Mitoxantrone resistance (MXR), 381, 383
- Molecular activation
mechanism
seven transmembrane receptors (7TM) and, 481–509
- Monoacylglycerol (MAG)
lipase, 104, 113
- Monod-Wyman-Changeux conformational switch, 504–6
- Multidrug resistance 1 (MDRI), 381, 387
- Multidrug resistance protein 1 (Mrp1), 381–83, 394, 397
- Multidrug resistance proteins (MRP), 327–28
- Multiple myeloma
bortezomib and, 189, 192, 202, 204–6
proteasome inhibitors and, 193–96
ubiquitin-proteasome pathway (UPP) and, 194
- Myeloma cells
treatment of, 197
- N**
- 19S proteasome, 191
- Neural crest
eye morphogenesis and, 465–66
- Neural crest cells (NCC), 456, 464–65
- Neuronal PAS domain protein-2 (NPAS-2)
carbon monoxide (CO) and, 416–20
- Neuronal plasticity
endocannabinoids and, 104–5
- Neuropathy
bortezomib clinical studies and, 202–3
- NF-E2 related factor 2 (Nrf2)
redox sensitive, 222
- NG-GPA, 155, 156, 165
- Nicotine
flavin-containing monooxygenase (FMO) and, 89–90
- Nitric oxide (NO), 411
- cardioprotective drugs and, 261–62
- caveolin-1 and, 431, 432
- covalent interaction with proteins, 244–49
- CYP enzymes and, 132–33
- extracellular regulation of, 249–55
- intracellular regulation of, 237–41
- nitrosothiols and, 244–45, 248
- novel roles for, 263
- oxidative stress and, 259–60
- pathophysiologic states affecting, 256–60
- pharmacologic intervention in physiology, 260–62
- pharmacologic paradigm of action of, 241–49
- protein radicals and, 248
- reactivity with metal centers, 241–44
- soluble guanylate cyclase (sGC) and, 241–42
- soluble guanylyl cyclase (sGC) and, 417–18
- Nitric oxide synthase (NOS), 235–64
CYP enzymes and, 132–33
drugs affecting, 261–62
expression and transcription of, 237–38
regulation of, 237–41
- Nitrosothiols
nitric oxide (NO) and, 244–45, 248
- Nitrosylation
nitric oxide (NO) and, 247–48
- Nitrotyrosine
inflammation and, 249
- Nitrovasodilator drugs, 260–62
- Non-Hodgkin lymphoma (NHL)

- bortezomib and, 189, 202-6
 NPI-0052
 proteasome inhibitor, 193
 NR1C3, 1, 9, 16-22, 25-27
 NR1I2, 42
 Nuclear compartmentation
 of glutathione (GSH), 217-18
 Nuclear factor-kappa B (NF- κ B)
 proteasome inhibitors and, 195-98
 redox sensitive, 221-22
 Nuclear receptors, 8-11
 CYPs and, 46
 regulation of gene expression by, 10
 Nuclear redox, 215-29
 measured by Trx1, 220
 new methods to measure, 218-20
 transcription factor regulation and, 221-23
- O**
 Obesity
 macrophages and, 4
 Organogenesis
 retinoic acid receptors (RARs) and, 454-56
 Organotypic models
 tumor proteolysis and, 301, 309
 Oxidative stress, 215-29
 CYP downregulation by, 128
 endothelial nitric oxide synthase (eNOS) and, 259-60
 microcompartmentation of, 228
 mitochondrial thioredoxin and, 224-25
 new definition of, 216-17
 nitric oxide (NO) and, 259-60
- plasma membrane and, 225-28
 Oxygen
 sensing, 430
- P**
 p27
 CDC34 and, 195
 future cancer therapies and, 195
 malignant cells and, 194
 proteasome inhibition and, 197
 p53
 proteasome inhibitors and, 196-97
 P-glycoprotein (P-gp)
 ABCG2 and, 381, 383, 387, 393-96
 chemoresistance and, 198
 multidrug resistance gene and, 327
 p38 mitogen-activated protein kinase (MAPK)
 anti-proliferative effect of, 424-26
 apoptosis and, 422-23
 carbon monoxide (CO) and, 413, 420-22, 428, 429, 431, 432
 cell cycle and, 423-24
 inflammation and, 426-28
 P2 receptors
 inflammation and, 290-92
 platelet function and, 277-92
 PA200
 proteasome activator, 191
 PA700
 proteasome activator, 191
 Palmitoylation
 nitric oxide synthase (NOS) activity and, 239-40
 Pegylated liposomal doxorubicin
 bortezomib and, 204
- Peroxisome
 proliferator-activated receptor- α (PPAR- α), 1, 9, 12-16, 24-26, 42, 44, 46, 47
 atherosclerosis and, 14-15
 downregulation of CYP and, 131
 humanized mice, 54-55
 Peroxisome
 proliferator-activated receptor- δ (PPAR- δ), 1, 9, 22-26
 Peroxisome
 proliferator-activated receptor- λ (PPAR- λ), 1, 9, 16-22, 25-27
 Peroxisome
 proliferator-activated receptors (PPARs), 1-27
 structure and function of, 9-10
 Pharmacogenomics
 acute leukemia and, 317-40
 explained, 320
 future of, 339-40
 Pheophorbide
 ABCG2 and, 395
 Philadelphia
 chromosome-positive acute lymphoblastic leukemia (ALL), 334
 Phosphatidylethanolamine-binding protein (PBP), 155, 156, 166, 167, 172
 Phosphatidylinositol-3 kinase (PI3K)
 ABCG2 and, 390-91
 endothelial nitric oxide synthase (eNOS) and, 254-55
 Phospholipase C (PLC)
 family of, 358-59
 isozymes, 355-73
 structure of, 359-64
 Phospholipases

- diverging class of, 360-62
- Phosphorylation, 133
- endothelial nitric oxide synthase (eNOS) and, 254-55
- nitric oxide synthase (NOS) isoforms and, 240
- Plasma membrane
- oxidative stress at, 225-28
- redox signaling at, 225-28
- Platelet(s)
- arterial thrombus formation and, 278-79
- refractory state of, 283-84
- Platelet P2 receptors, 277-92
- angiogenesis and, 290-92
- atherosclerosis and, 290-92
- inflammation and, 290-92
- targets for antithrombotic drugs, 285-86
- POH1
- multiple myeloma and, 194
- Polymorphisms
- of P2Y receptors, 284-85
- treatment failure and, 318
- Position 482
- ABCG2 and, 397-98
- Posttranscriptional regulation
- flavin-containing monooxygenase (FMO) and, 71
- Pregnant X receptor (PXR), 42
- CYPs and, 46
- humanized mice, 53-54
- Protease activity
- imaging assays and, 302-4
- Proteases
- tumors and, 301-11
- Proteasome inhibition
- molecular sequelae of, 195-97
- Proteasome inhibitor(s)
- antitumor activity of, 205
- as antitumor agents, 193-94
- antitumor effect, 195-97
- bortezomib, 200-6
- cancer therapy, 189-206
- chemoresistance to, 199-200
- development of, 191-93
- sensitize cells to
- therapeutics, 197-99
- targets of, 195-97
- transformed cells and, 194-95
- Protein(s)
- breast cancer-resistance protein, 328
- multidrug resistance proteins (MRP), 327-28
- nitric oxide (NO) covalent interaction with, 244-49
- S-nitrosylation and, 245-47
- Protein binding partners
- for G protein subunits, 155-63, 173
- Protein kinases
- CYP downregulation and, 129, 133
- Protein radicals
- nitric oxide (NO) and, 248
- Protein structure
- flavin-containing monooxygenase (FMO) and, 80-81
- Proteolysis
- in four dimensions, 307, 309
- migration and invasion and, 307-9
- of misfolded proteins, 197
- in three dimensions, 306-7, 309
- tumor
- imaging of, 301-11
- in two dimensions, 305-6
- in vitro by live tumor cells, 304-9
- Protoporphyrin
- ABCG2 and, 395, 396
- PS-341, 192
- See also Bortezomib
- P2T receptor, 278
- antagonists, 288
- P2X₁
- congenital deficiencies and, 284
- platelet function and, 277, 281-82
- P2X₁ receptor
- antiplatelet compounds and, 289-90
- inflammation and, 291
- thrombus formation and, 282
- PXR
- ABCG2 and, 384
- P2Y₁₂
- competitive antagonists of, 287-88
- congenital deficiencies and, 284
- platelet function and, 277, 280-82
- P2Y₁₂ antagonists, 291
- P2Y receptor(s)
- platelet function and, 277-82
- polymorphisms of, 284-85
- thrombus formation and, 282-83
- P2Y₁ receptor, 290
- angiogenesis and, 291
- antiplatelet compounds and, 288-89
- desensitization, 283-84
- inflammation and, 291
- thrombus formation and, 282-83
- P2Y₂ receptor
- angiogenesis and, 291
- P2Y₁₂ receptor(s)
- angiogenesis and, 291
- inflammation and, 290-91
- thrombus and, 283-85

Q

Quinone oxidoreductase
(NQO1), 323–24

R

Rac
phospholipase C (PLC)
isozymes and, 364–66

Radiation
combined with bortezomib,
198

Raf kinase interacting protein
(RKIP), 155, 156, 166,
167, 172

Ras
phospholipase C (PLC)
and, 366–68, 370–71

Ras family GTPases
phospholipase C (PLC)
isozymes and, 355–73

Redox
nuclear and
mitochondrial, 215–29
signaling, 215–29
microcompartmentation
of, 228
nuclear and cytoplasmic
redox states during,
220–21
plasma membrane and,
225–28
signaling and control,
223–25
states
mitochondrial, 223–24

Redox sensitive green
fluorescent proteins
(roGFP), 218–20, 225

Reduced folate carrier (RFC)
drug resistance and,
328–29

Regulator of G protein
signaling (RGS)
accessory proteins and,
153, 171, 172

Retinal function
rhodopsin activation

and, 497
Retinaldehyde
dehydrogenases, 454,
456, 468, 469

Retinoic acid (RA)
signaling, 451–71

Retinoic acid receptors
(RARs), 451–71
development and, 464–66
hindbrain segmentation
and, 465

mesectodermal derivatives
and, 456, 458–59

Retinoic acid signaling,
451–71
retinoic acid receptors
(RARs) and, 454–64
rexinoid receptors (RXRs)
and, 454–64

Retinoid nuclear receptors,
451–71

Retinoid receptor functions
in vitro studies, 452–54

Retinoids, 451
teratogenicity and, 466–69

Retinol, 451

Rexinoid receptors (RXRs),
451–71
development and, 460–64

Rho
phospholipase C (PLC)
and, 364–65, 368–70, 372

Rhodopsin
retinal functions and, 497
seven transmembrane
receptors (7TM) and, 508

Rhodopsin-like seven
transmembrane
receptors (7TM)

agonist binding in, 483–86
Ric-8, 155, 157, 166

Rpn11
multiple myeloma and, 194

S

S-nitrosylation
endothelial nitric oxide

synthase (eNOS) and,
240–41

protein activity and,
245–47

Schizophrenia

clozapine and, 127

Selective estrogen receptor
modulators (SERMs), 27

Selective PPAR modulators
(SPPARMs), 27

Seven transmembrane
receptors (7TM),
481–509

activated through metal ion
sites, 489–90

agonist binding in, 483–86

dynamic *versus* rigid
interfaces, 506–7

locks and keys for, 502–4

toggle switch activation of,
481–509

Sex hormones

ABCG2 and, 385

Shear forces

thrombus formation and,
282–83

Signal transduction

accessory and G proteins
and, 151–73

thiol/disulfide redox and,
216–17

transmembranes and, 488

Single-nucleotide

polymorphism(s)
(SNPs), 318–19

ABCG2 and, 386, 398

flavin-containing
monooxygenase (FMO)
and, 69–71, 74–79, 86

Site Directed Drug Discover,
482, 509

Skp2


future cancer therapies and,
195

SLC19A1

drug resistance and,
328–29

- Smoking
 flavin-containing
 monooxygenase (FMO)
 and, 89–90
- Soluble guanylate cyclase
 (sGC)
 nitric oxide (NO) activates,
 241–42
- Soluble guanylyl cyclase
 (sGC)
 carbon monoxide (CO)
 and, 417–20, 429
 caveolin-1 and, 432
- Sphingolipids
 microdomains and, 431
- Sphingosine 1-phosphate
 (S1P)
 endothelial nitric oxide
 synthase (eNOS) and,
 251–52
- Statins, 261
 atherosclerosis and, 2–3
 coronary artery disease
 (CAD), 2–3
 drugs in combination with,
 3
 peroxisome
 proliferator-activated
 receptor (PPAR) agonists
 and, 27
- Stem cells
 ABCG2 in, 387–88
- Steroid X receptor (SXR)
 CYPs and, 46
- Strokes
 atherosclerosis, 1
- Sulfotransferase (SULT),
 123, 136
- SUMMIT study, 202, 204
- T**
- 20S proteasome, 190–92
- T cells
 carbon monoxide (CO)
 and, 428–29
- Teratogenicity
 retinoids and, 466–69
- Thalidomide
 bortezomib and, 205
- Therapeutics
 proteasome inhibitors
 sensitize cells to,
 197–99
- Thiazolidinediones (TZDs),
 16, 21
- Thienopyridine(s), 287
- antithrombotic, 285
- Thiopurine
 S-methyltransferase
 (TPMT), 329–30
 chemotherapeutic agents
 and, 324–26
- Thiopurines
 acute lymphoblastic
 leukemia (ALL) and,
 329–31
- Thioredoxin
 mitochondrial, 224–25
- Thrombin
 endothelial nitric oxide
 synthase (eNOS) and, 254
- Thrombosis, 277–78
 P2 receptor and, 278
 P2Y₁₂ antagonists and, 288
 P2Y₁ receptor and, 288–89
- Thromboxane A₂ (TXA₂)
 thrombus formation and,
 279–81
- Thrombus formation, 278–79
 flow conditions and,
 282–83
 P2 receptors and, 282–83
 platelet activation and,
 278–79
 shear forces and, 282–83
- Thymidylate synthetase
 acute lymphoblastic
 leukemia (ALL) and, 333
- Ticlopidine, 285
- Toggle switch activation
 ghrelin receptor family
 and, 502
 of seven transmembrane
 receptors (7TM), 481–509
- Torcetrapib, 3
- Total parenteral nutrition
 (TPN)
 flavin-containing
 monooxygenase (FMO)
 and, 82–83
- Toxins
 cytochrome P450 enzymes
 and, 41
- Transcription factor
 regulation
 nuclear and cytoplasmic
 redox couples and,
 221–23
- Transcriptional regulation
 of CYP enzymes, 129–31
 flavin-containing
 monooxygenase (FMO)
 and, 70–71
- Transformed cells
 proteasome inhibitors and,
 194–95
- Transmembrane (TM)
 receptors
 main ligand-binding pocket
 and, 488–91
 movements of, 486–88,
 490–96
- Trimethylamine (TMA)
 flavin-containing
 monooxygenase (FMO)
 and, 66, 69, 70, 72, 73,
 76–78, 83, 86–87
- Troglitazone, 21
- Trx
 mitochondrial, 224
- Trx1, 222, 229
 nuclear redox state
 measured by, 220
- Tubulin, 157, 163, 165, 166
- Tumor(s)
 ABCG2 and, 392
 bortezomib trial and,
 203
 chronic inflammation and,
 127
 microenvironment

- neoplastic progression
and, 309
- proteolysis
imaging of, 301-11
in vivo, 309-10
sensitivity to therapeutics,
197
- Tunicamycin
myeloma cells and, 197
- Turpentine
animals treated with, 125,
129-30, 137-39
- U**
- Ubiquitin-proteasome
pathway (UPP)
malignant transformation
and, 194, 205
multiple myeloma and, 194
proteolysis through,
190-91
- UDP-glucuronosyltransferase
(UGT), 123, 135
chemotherapeutic agents
and, 324, 326
- Ulcerative colitis
CYP activity and, 126
- Unfolded protein response
(UPR), 197
- V**
- Vascular endothelial cells
monocyte adhesion to,
226-27
- Vascular endothelial growth
factor (VEGF)
endothelial nitric oxide
synthase (eNOS) and,
252-53
- Vitamin A deficiency (VAD)
syndrome, 451-52,
454-59, 463
- Vitamin C
antioxidant, 260
- Von Willebrand factor (vWF)
platelet activation and,
278-79
- X**
- Xenobiotic receptor
humanized mice
cytochrome P450 and,
41-56
- Xenobiotic receptors
metabolism and, 44,
46-47
- Xenobiotics
biological mediators in
response to,
43-47
CYPs and, 42
cytochrome P450s and,
43-44



CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 42-46

A

Abdel-Rahman SM, 44:111-36
 Adams JP, 42:135-63
 Aitken AE, 46:123-49
 Allio T, 43:125-47
 Altman RB, 42:113-33
 Ambler SK, 45:657-87
 Anders MW, 45:147-76
 Anderson RGW, 45:587-603
 Anderson KC, 45:465-76
 Angers S, 42:409-35
 Arav-Boger R, 45:565-85
 Arnason JT, 45:203-26
 Aschner M, 44:87-110
 Atkins WM, 45:291-310
 Aweeka F, 44:499-523

B

Baldwin LA, 43:175-97
 Bale TL, 44:525-58
 Barber DL, 42:527-52
 Barnes PJ, 42:81-98
 Bearss DJ, 43:359-79
 Benz CC, 45:495-528
 Besirli CG, 44:451-74
 Beutler B, 43:609-28
 Bicknell R, 44:219-38
 Bieck PR, 45:227-46
 Blaschke TF, 44:499-523
 Blakely RD, 43:521-44
 Blumer JB, 46:151-87
 Boekelheide K, 43:125-47
 Bogdanffy MS, 43:485-520
 Bolt HM, 43:485-520
 Bournier CD, 42:259-81
 Bouvier M, 42:409-35
 Brady AE, 44:559-609

Briggs CJ, 45:203-26
 Brown RD, 45:657-87

C

Calabrese EJ, 43:175-97
 Caro AA, 44:27-42
 Caron MG, 43:261-84
 Cashman JR, 46:65-100
 Casida JE, 45:247-68
 Cavallo-Medved D, 46:301-15
 Cederbaum AI, 44:27-42
 Chambon P, 46:451-80
 Chauhan D, 45:465-76
 Chen J-F, 45:385-412
 Cheok MH, 46:317-53
 Choi AMK, 46:411-49
 Chuang D-M, 45:269-90
 Cidlowski JA, 42:259-81
 Claiborne A, 44:325-47
 Clancy CE, 43:441-61
 Colamarino SA, 44:399-421
 Collins S, 44:297-323
 Conney AH, 43:1-30
 Coon MJ, 45:1-25
 Correia MA, 45:439-64
 Costa LG, 44:87-110
 Coyle JT, 42:165-79

D

de Boer AG, 43:629-56
 Denison MS, 43:309-34
 Denker SP, 42:527-52
 Ding X, 43:149-73
 Drummond DC, 45:495-528
 DuBois RN, 42:55-80
 Ducruet AP, 45:725-50
 Dudzinski DM, 46:235-76

E

Eichelbaum M, 43:285-307
 Elling CE, 46:481-519
 Elsayed Y, 43:199-231
 Embree-Ku ME, 43:125-47
 Esteller M, 45:629-56
 Eudy JD, 42:181-208
 Evans WE, 46:317-53

F

Fernandez EJ, 42:469-99
 Finnell RH, 42:181-208
 Fisone G, 44:269-96
 Flanagan JU, 45:51-88
 Fleming SL, 43:125-47
 Foster BC, 45:203-26
 Fredholm BB, 45:385-412
 Frimurer TM, 46:481-519
 Fromm MF, 43:285-307
 Fukuto JM, 45:335-55
 Fung H-L, 44:67-85

G

Gachet C, 46:277-300
 Gage FH, 44:399-421
 Gaillard PJ, 43:629-56
 Gainetdinov RR, 43:261-84
 Gandhi M, 44:499-523
 Gelineau-van Waes J, 42:181-208
 Ghyselinck NB, 46:451-80
 Girault J-A, 44:269-96
 Giri SN, 43:73-95
 Go Y-M, 46:215-34
 Gold MS, 44:371-97
 Golding BT, 42:325-48
 Gonzalez FJ, 46:41-64
 Goodman JJ, 42:501-25
 Goodwin B, 42:1-23

Greenblatt RM, 44:499-523
 Greengard P, 44:269-96
 Greif D, 46:235-76
 Grenard P, 45:605-28
 Griffin RJ, 42:325-48
 Guengerich FP, 45:27-49
 Guo Z, 45:495-528

H

Hall SJ, 43:125-47
 Hammock BD, 45:311-33
 Hansen JM, 46:215-34
 Hardcastle IR, 42:325-48
 Harden TK, 46:355-79
 Harris AL, 44:219-38
 Hayes JD, 45:51-88
 Hengstler JG, 43:485-520
 Hideshima T, 45:465-76
 Highfield Nickols H,
 44:559-609
 Hogg N, 42:585-600
 Holbro T, 44:195-217
 Holst B, 46:481-519
 Hough C, 45:269-90
 Hunter JC, 44:371-97
 Hurley LH, 43:359-79
 Hynes NE, 44:195-217

I

Igarashi J, 46:235-76
 Ignarro LJ, 43:97-123

J

Javitch JA, 42:437-67
 Johnson EM Jr, 44:451-74
 Johnson KJ, 43:125-47
 Jones DP, 46:215-34
 Jones JP, 45:477-94
 Jowsey IR, 45:51-88
 Juliano RL, 42:283-323
 Julien B, 45:605-28
 Jupe SC, 44:43-66

K

Kamendulis LM, 44:239-67
 Kaminsky LS, 43:149-73
 Karplus PA, 44:325-47

Kass RS, 43:441-61
 Kauffman RE, 44:111-36
 Keefer LK, 43:585-607
 Kenakin T, 42:349-79
 Kim D, 45:27-49
 Kim G, 43:199-231
 Kim HP, 46:411-49
 Kim RB, 44:137-66
 Kinsel JF, 43:463-84
 Kirpotin DB, 45:495-528
 Kitteringham NR,
 45:177-202
 Klaunig JE, 44:239-67
 Klein TE, 42:113-33
 Klier SA, 42:1-23
 Kootstra NA, 43:413-39
 Krishnamurthy P, 46:381-410
 Kroetz DL, 45:413-38
 Kurokawa J, 43:441-61
 Kurzrock R, 45:357-84
 Kwon EJ, 43:125-47

L

Lafontan M, 45:119-46
 Lai J, 44:371-97
 Lanier SM, 46:151-87
 Laufs U, 45:89-118
 Lazo JS, 45:725-50
 Lee W, 44:137-66
 Li AC, 46:1-39
 Liao JK, 45:89-118
 Lie DC, 44:399-421
 Liggett SB, 43:381-411
 Limbird LE, 44:559-609
 Liu X, 44:349-70
 Lolis E, 42:469-99
 Long CS, 45:657-87
 Lotersztajn S, 45:605-28
 Lugthart S, 46:317-53

M

Mackenzie PI, 44:1-25
 Mackie K, 46:101-22
 Maggs JL, 45:177-202
 Maliakal P, 42:25-54
 Mallat A, 45:605-28
 Mark M, 46:451-80

Marnett LJ, 42:55-80
 Martin TL, 44:297-323
 Masino SA, 45:385-412
 McCammon AJ, 43:31-45
 McGraw DW, 43:381-411
 McKinnon RA, 44:1-25
 Meng X, 42:25-54
 Michel JJ, 42:235-57
 Michel T, 46:235-76
 Miners JO, 44:1-25
 Ming G-I, 44:399-421
 Miranda KM, 45:335-55
 Mitchell MD, 45:657-87
 Möhler H, 44:475-98
 Moin K, 46:301-15
 Monga M, 43:199-231
 Morgan ET, 46:123-49
 Morisseau C, 45:311-33
 Mundo-Paredes E, 45:439-64

N

Nagy SR, 43:309-34
 Nairn AC, 44:269-96
 Napoli C, 43:97-123
 Nass R, 43:521-44
 Neu J, 42:381-408
 Nguyen T, 43:233-60
 Nishi A, 44:269-96
 Noble CO, 45:495-528

O

Oesch F, 43:485-520
 Orlowski RZ, 46:189-213

P

Palinski W, 46:1-39
 Park BK, 45:177-202
 Patel SR, 43:125-47
 Petralia RS, 43:335-58
 Pickett CB, 43:233-60
 Pirmohamed M,
 45:177-202
 Podgorski I, 46:301-15
 Poole LB, 44:325-47
 Pootoolal J, 42:381-408
 Porreca F, 44:371-97
 Potter WZ, 45:227-46

Prybylowski K, 43:335-58
Putney LK, 42:527-52

R

Rasoulpour RJ, 43:125-47
Redinbo MR, 42:1-23
Rees S, 44:43-66
Rettie AE, 45:477-94
Rezler EM, 43:359-79
Richardson TA, 46:123-49
Robidoux J, 44:297-323
Rosenkilde MM, 46:481-519
Rosenquist TH, 42:181-208
Rudolph U, 44:475-98
Ryter SW, 46:411-49

S

Sadeghi S, 45:439-64
Salahpour A, 42:409-35
Sameni M, 46:301-15
Sans N, 43:335-58
Sato H, 45:689-723
Sato M, 46:151-87
Sausville EA, 43:199-231
Schenk D, 43:545-84
Schnellmann RG,
44:349-70
Schoenfeld HA, 43:125-47
Schuetz JD, 46:381-410
Schwab M, 43:285-307
Scott GK, 45:495-528
Scott JD, 42:235-57
Selkoe DJ, 43:545-84
Senatorov VV, 45:269-90
Shapiro TA, 45:565-85

Sherratt PJ, 43:233-60
Shi L, 42:437-67
Shitara Y, 45:689-723
Simon V, 46:151-87
Simpson LL, 44:167-93
Sloane BF, 46:301-15
Small KM, 43:381-411
Smith PA, 44:1-25
Soldin OP, 44:87-110
Sondek J, 46:355-79
Song H, 44:399-421
Sorich MJ, 44:1-25
Standly S, 43:335-58
Straus SE, 43:463-84
Sugiyama Y, 45:689-723
Svenningsson P, 44:269-96
Svensson CI, 42:553-83
Sweatt JD, 42:135-63
Switzer CH, 45:335-55
Syversen T, 44:87-110

T

Tan CM, 44:559-609
Tateyama M, 43:441-61
Taylor SL, 42:99-112
Teixeira-Clerc F, 45:605-28
Thompson S, 43:125-47
Tibes R, 45:357-84
Tomizawa M, 45:247-68
Trent J, 45:357-84
Tsai G, 42:165-79

V

Vale WW, 44:525-58
van der Sandt ICI, 43:629-56

Van Vleet T, 44:349-70
Vaugeois J-M, 45:385-412
Verma IM, 43:413-39
Vitalone A, 44:87-110
Vogt A, 45:725-50
Voorhees PM, 46:189-213

W

Wang LH, 44:451-74
Wang Q, 44:559-609
Watson RE, 42:501-25
Wehrens XHT, 43:441-61
Wei L-N, 43:47-72
Wentholt RJ, 43:335-58
Wess J, 44:423-50
White MA, 45:587-603
Williams DP, 45:177-202
Wink DA, 45:335-55
Wipf P, 45:725-50
Wise A, 44:43-66
Wong CF, 43:31-45
Wright GD, 42:381-408

Y

Yaksh TL, 42:553-83
Yang CS, 42:25-54
Yu A-M, 46:41-64

X

Xu F, 45:413-38

Z

Zhang J, 46:65-100
Zhang Y, 45:529-64
Zhang Z-Y, 42:209-34

CHAPTER TITLES, VOLUMES 42-46

Prefatory

PHARMACOLOGY

- | | | |
|---|---------|---------|
| Cytochrome P450: Nature's Most Versatile
Biological Catalyst | MJ Coon | 45:1-25 |
|---|---------|---------|

TOXICOLOGY

- | | | |
|--|-----------|---------|
| Induction of Drug-Metabolizing Enzymes:
A Path to the Discovery of Multiple
Cytochromes P450 | AH Conney | 43:1-30 |
|--|-----------|---------|

General Topics in Pharmacology and Toxicology

- | | | |
|--|--|-----------|
| Hormesis: The Dose-Response Revolution | EJ Calabrese,
LA Baldwin | 43:175-97 |
| Regulatory Mechanisms Controlling Gene
Expression Mediated by the Antioxidant
Response Element | T Nguyen,
PJ Sherratt,
CB Pickett | 43:233-60 |
| Voltage-Gated Sodium Channels and
Hyperalgesia | J Lai J, F Porreca,
JC Hunter,
MS Gold | 44:371-97 |

RECEPTORS

- | | | |
|--|--|-----------|
| Glutamatergic Mechanisms in
Schizophrenia | G Tsai, JT Coyle | 42:165-79 |
| Drug Efficacy at G Protein-Coupled
Receptors | T Kenakin | 42:349-79 |
| Dimerization: An Emerging Concept for G
Protein-Coupled Receptor Ontogeny and
Function | S Angers,
A Salahpour,
M Bouvier | 42:409-35 |
| The Binding Site of Aminergic G
Protein-Coupled Receptors: The
Transmembrane Segments and Second
Extracellular Loop | L Shi, JA Javitch | 42:437-67 |
| Retinoid Receptors and Their Coregulators | L-N Wei | 43:47-72 |

Trafficking of NMDA Receptors	RJ Wenthold, K Prybylowski, S Standly, N Sans, RS Petralia	43:335-58
The Identification of Ligands at Orphan G-Protein Coupled Receptors	A Wise, SC Jupe, S Rees	44:43-66
ErbB Receptors: Directing Key Signaling Networks Throughout Life	T Holbro, NE Hynes	44:195-217
Voltage-Gated Sodium Channels and Hyperalgesia	J Lai J, F Porreca, JC Hunter, MS Gold	44:371-97
Membrane Trafficking of G Protein-Coupled Receptors	CM Tan, AE Brady, H Highfield Nickols, Q Wang, LE Limbird	44:559-609
Actions of Adenosine at Its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412
Peroxisome Proliferator-Activated Receptors: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis	AC Li, W Palinski	46:1-39
Cannabinoid Receptors as Therapeutic Targets	K Mackie	46:101-22
Accessory Proteins for G Proteins: Partners in Signaling	M Sato, JB Blumer, V Simon, SM Lanier	46:151-87
Regulation of Platelet Functions by P2 Receptors	C Gachet	46:277-300
Regulation of Phospholipase C Isozymes by Ras Superfamily GTPases	TK Harden, J Sondek	46:355-79
Function of Retinoid Nuclear Receptors: Lessons from Genetic and Pharmacological Dissections of the Retinoic Acid Signaling Pathway During Mouse Embryogenesis	M Mark, NB Ghyselinck, P Chambon	46:451-80

Molecular Mechanism of 7TM Receptor Activation—A Global Toggle Switch Model	TW Schwartz, TM Frimurer, B Holst, MM Rosenkilde, CE Elling	46:481–519
SIGNAL TRANSDUCTION		
Cellular Mechanisms for the Repression of Apoptosis	CD Bortner, JA Cidlowski	42:259–81
Protein Sulfenic Acids in Redox Signaling	LB Poole, A Karplus, A Claiborne	44:325–47
Signaling Networks in Living Cells	MA White, RGW Anderson	45:587–603
Nuclear and Mitochondrial Compartmentation of Oxidative Stress and Redox Signaling	JM Hansen, Y Go, DP Jones	46:215–34
Regulation of Phospholipase C Isozymes by Ras Superfamily GTPases	TK Harden J Sondek	46:355–79
CO as a Cellular Signaling Molecule	HP Kim, SW Ryter, AMK Choi	46:411–49
SYNAPTIC FUNCTIONS		
Molecular Psychology: Roles for the ERK MAP Kinase Cascade in Memory	JP Adams, JD Sweatt	42:135–63
Identification of the Major Steps in Botulinum Toxin Action	LL Simpson	44:167–93
DARPP-32: An Integrator of Neurotransmission	P Svenningsson, A Nishi, G Fisone, J-A Girault, AC Nairn, P Greengard	44:269–96
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423–50
ION CHANNELS		
Voltage-Gated Sodium Channels and Hyperalgesia	J Lai, F Porreca, JC Hunter, MS Gold	44:371–97
TRANSPORTERS		
AKAP-Mediated Signal Transduction	JJC Michel, JD Scott	42:235–57

The Changing Face of the Na^+/H^+ Exchanger, NHE1: Structure, Regulation, and Cellular Actions	LK Putney, SP Denker, DL Barber	42:527-52
Monoamine Transporters: From Genes to Behavior	RR Gainetdinov, MG Caron	43:261-84
Genetic Polymorphisms of the Human MDR1 Drug Transporter	M Schwab, M Eichelbaum, MF Fromm	43:285-307
The <i>Caenorhabditis elegans</i> Dopaminergic System: Opportunities for Insights into Dopamine Transport and Neurodegeneration	R Nass, RD Blakely	43:521-44
The Role of Drug Transporters at the Blood-Brain Barrier	AG de Boer, ICJ van der Sandt, PJ Gaillard	43:629-56
Role of ABCG2/BCRP in Biology and Medicine	P Krishnamurthy, JD Schuetz	46:381-410

ENZYMES

Regulation of CYP3A Gene Transcription by the Pregnane X Receptor	B Goodwin, MR Redinbo, SA Kliewer	42:1-23
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112
The Biochemistry and Physiology of S-Nitrosothiols	N Hogg	42:585-600
Telomere Inhibition and Telomere Disruption as Processes for Drug Targeting	EM Rezler, DJ Bearss, LH Hurley	43:359-79
The Role of Calpain in Oncotic Cell Death	X Liu, T Van Vleet, RG Schnellmann	44:349-70
Mixed-Lineage Kinases: A Target for the Prevention of Neurodegeneration	LH Wang, CG Besirli, EM Johnson Jr.	44:451-74
Glutathione Transferases	JD Hayes, JU Flanagan, IR Jowsey	45:51-88

Non-Michaelis-Menten Kinetics in Cytochrome P450-Catalyzed Reactions	WM Atkins	45:291-310
Clinical Development of Histone Deacetylase Inhibitors	DC Drummond, CO Noble, DB Kirpotin, Z Guo, GK Scott, CC Benz	45:495-528
Evaluation of Drug-Drug Interaction in the Hepatobiliary and Renal Transport of Drugs	Y Shitara, H Sato, Y Sugiyama	45:689-723
The Regulation and Pharmacology of Endothelial Nitric Oxide Synthase	DM Dudzinski, J Igarashi, D Greif, T Michel	46:235-76
CHEMICAL AGENTS		
Inhibition of Carcinogenesis by Tea	CS Yang, P Maliakal, X Meng	42:25-54
2,5-Nitric Oxide-Releasing Drugs	C Napoli, LJ Ignarro	43:97-123
Hexandione-Induced Testicular Injury	K Boekelheide, SL Fleming, T Allio, ME Embree-Ku, SJ Hall, KJ Johnson, EJ Kwon, SR Patel, RJ Rasoulpour, HA Schoenfeld, S Thompson	43:125-47
Progress Toward Clinical Application of the Nitric Oxide-Releasing Diazeniumdiolates	LK Keefer	43:585-607
Nitroxyl (HNO): Chemistry, Biochemistry, and Pharmacology	JM Fukuto, CH Switzer, KM Miranda, DA Wink	45:335-55
PEPTIDES AND PROTEINS		
Protein Allergenicity Assessment of Foods Produced Through Agricultural Biotechnology	SL Taylor	42:99-112

BIOTRANSFORMATION

- | | | |
|--|---|------------|
| Regulation of CYP3A Gene Transcription
by the Pregnane X Receptor | B Goodwin,
MR Redinbo,
SA Kliewer | 42:1-23 |
| Human Extrahepatic Cytochromes P450:
Function in Xenobiotic Metabolism and
Tissue-Selective Chemical Toxicity in
the Respiratory and Gastrointestinal
Tracts | X Ding, LS Kaminsky | 43:149-73 |
| Predicting Human Drug Glucuronidation
Parameters: Application of In Vitro and
In Silico Modeling Approaches | JO Miners,
PA Smith,
MJ Sorich,
RA McKinnon,
PI Mackenzie | 44:1-25 |
| Oxidative Stress, Toxicology, and
Pharmacology of CYP2E1 | AA Caro,
AI Cederbaum | 44:27-42 |
| Cytochrome P450 Activation of
Arylamines and Heterocyclic Amines | D Kim,
FP Guengerich | 45:27-49 |
| Formation and Toxicity of Anesthetic
Degradation Products | MW Anders | 45:147-76 |
| The Role of Metabolic Activation in
Drug-Induced Hepatotoxicity | BK Park,
NR Kitteringham,
JL Maggs,
M Pirmohamed,
DP Williams | 45:177-202 |
| Epoxide Hydrolases: Mechanisms,
Inhibitor Designs, and Biological Roles | C Morisseau,
BD Hammock | 45:311-33 |
| Tyrosine Kinase Inhibitors and the Dawn
of Molecular Cancer Therapeutics | R Tibes, J Trent,
R Kurzrock | 45:357-84 |
| Cytochrome P450 Ubiquitination:
Branding for the Proteolytic Slaughter? | MA Correia,
S Sadeghi,
E Mundo-Paredes | 45:439-64 |
| Clinical and Toxicological Relevance of
CYP2C9: Drug-Drug Interactions and
Pharmacogenetics | AE Rettie, JP Jones | 45:477-94 |
| Cytochrome P450 and Xenobiotic
Receptor Humanized Mice | FJ Gonzalez,
A-M Yu | 46:41-64 |

Human Flavin-Containing Monooxygenases	JR Cashman, J Zhang	46:65-100
Regulation of Drug-Metabolizing Enzymes and Transporters in Inflammation	AE Aitken, TA Richardson, ET Morgan	46:123-49
The Proteasome and Proteasome Inhibitors in Cancer Therapy	PM Voorhees, RZ Orlowski	46:189-213
PHARMACOKINETICS/TOXICOKINETICS		
The Integration of Pharmacokinetics and Pharmacodynamics: Understanding Dose-Response	SM Abdel-Rahman, RE Kauffman	44:111-36
Transporters and Renal Drug Elimination	W Lee, RB Kim	44:137-66
Natural Health Products and Drug Disposition	BC Foster, JT Arnason, CJ Briggs	45:203-26
Evaluation of Drug-Drug Interaction in the Hepatobiliary and Renal Transport of Drugs	Y Shitara, H Sato, Y Sugiyama	45:689-723
Role of ABCG2/BCRP in Biology and Medicine	P Krishnamurthy, JD Schuetz	46:381-410
CANCER AND CARCINOGENESIS		
Inhibition of Carcinogenesis by Tea	CS Yang, P Maliakal, X Meng	42:25-54
COX-2: A Target for Colon Cancer Prevention	LJ Marnett, RN DuBois	42:55-80
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Altered DNA Methylation: A Secondary Mechanism Involved in Carcinogenesis	JI Goodman, RE Watson	42:501-25
Signal Transduction-Directed Cancer Treatments	EA Sausville, Y Elsayed, M Monga, G Kim	43:199-231
The Role of Oxidative Stress in Carcinogenesis	JE Klaunig, LM Kamendulis	44:239-67

Proteasome Inhibition in Multiple Myeloma: Therapeutic Implication	D Chauhan, T Hideshima, KC Anderson	45:465-76
Aberrant DNA Methylation as a Cancer-Inducing Mechanism	M Esteller	45:629-56
Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer's Disease	AP Ducruet, A Vogt, P Wipf, JS Lazo	45:725-50
Functional Imaging of Tumor Proteolysis	BF Sloane, M Sameni, I Podgorski, D Cavallo-Medved, K Moin	46:301-15
CLINICAL THERAPEUTICS		
Glycopeptide Antibiotic Resistance	J Pootoolal, J Neu, GD Wright	42:381-408
Complementary and Alternative Therapeutics: Rigorous Research is Needed to Support Claims	JF Kinsel, SE Straus	43:463-84
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50
Pleiotropic Effects of Statins	JK Liao, U Laufs	45:89-118
The Magic Bullets and Tuberculosis Drug Targets	Y Zhang	45:529-64
Molecular Mechanisms of Resistance in Antimalarial Chemotherapy: The Unmet Challenge	R Arav-Boger, TA Shapiro	45:565-85
Hepatic Fibrosis: Molecular Mechanisms and Drug Targets	S Lotersztajn, B Julien, F Teixeira-Clerc, P Grenard, A Mallat	45:605-28
Pharmacogenomics of Acute Leukemia	MH Cheok, S Lugthart, WE Evans	46:317-53
DRUG DEVELOPMENT SCIENCE		
Molecular Basis of Environmentally Induced Birth Defects	RH Finnell, J Gelineau-van Waes, JD Eudy, TH Rosenquist	42:181-208

Protein Tyrosine Phosphatases: Structure and Function, Substrate Specificity, and Inhibitor Development	Z-Y Zhang	42:209-34
Designing Inhibitors of Cyclin-Dependent Kinases	IR Hardcastle, BT Golding, RJ Griffin	42:325-48
Protein Flexibility and Computer-Aided Drug Design	CF Wong, JA McCammon	43:31-45
Gene Therapy with Viral Vectors	NA Kootstra, IM Verma	43:413-39
Biomarkers in Psychotropic Drug Development: Integration of Data across Multiple Domains	PR Bieck, WZ Potter	45:227-46
Systems		
Neurogenesis in the Adult Brain: New Strategies for Central Nervous System Diseases	D Lie, H Song, SA Colamarino, G Ming, F Gage	44:399-421
DEVELOPMENT AND AGING		
Developmental Neuropathology of Environmental Agents	LG Costa, M Aschner, A Vitalone, T Syversen, OP Soldin	44:87-110
Neonicotinoid Insecticide Toxicology: Mechanisms of Selective Action	M Tomizawa, JE Casida	45:247-68
MUSCLE AND ADIPOSE TISSUE		
β -Adrenergic Receptors and Regulation of Energy Expenditure: A Family Affair	J Robidoux, TL Martin, S Collins	44:297-323
Fat Cells: Afferent and Efferent Messages Define New Approaches to Treat Obesity	M Lafontan	45:119-46
IMMUNE SYSTEM/INFLAMMATION		
Signal Transduction by Cell Adhesion Receptors and the Cytoskeleton: Functions of Integrins, Cadherins, Selectins, and Immunoglobulin-Superfamily Members	RL Juliano	42:283-323

Structure, Function, and Inhibition of Chemokines	EJ Fernandez, E Lolis	42:469-99
Innate Immune Responses to Microbial Poisons: Discovery and Function of the Toll-Like Receptors	B Beutler	43:609-28
Regulation and Inhibition of Arachidonic Acid (omega)-Hydroxylases and 20-HETE Formation	DL Kroetz, F Xu	45:413-38
CENTRAL NERVOUS SYSTEM		
Glutamatergic Mechanisms in Schizophrenia	G Tsai, JT Coyle	42:165-79
The Spinal Phospholipase-Cyclooxygenase-Prostanoid Cascade in Nociceptive Processing	CI Svensson, TL Yaksh	42:553-83
Alzheimer's Disease: Molecular Understanding Predicts Amyloid-Based Therapeutics	DJ Selkoe, D Schenk	43:545-84
Neurogenesis in the Adult Brain: New Strategies for Central Nervous System Diseases	D Lie, H Song, SA Colamarino, G Ming, F Gage	44:399-421
Muscarinic Acetylcholine Receptor Knockout Mice: Novel Phenotypes and Clinical Implications	J Wess	44:423-50
Analysis of GABAA Receptor Function and Dissection of the Pharmacology of Benzodiazepines and General Anesthetics Through Mouse Genetics	U Rudolph, H Möhler	44:475-98
CRF and CRF Receptors: Role in Stress Responsivity and Other Behaviors	TL Bale, WW Vale	44:525-58
Glyceraldehyde-3-Phosphate Dehydrogenase, Apoptosis, and Neurodegenerative Diseases	D-M Chuang, C Hough, VV Senatorov	45:269-90
Actions of Adenosine at its Receptors in the CNS: Insights from Knockouts and Drugs	BB Fredholm, J-F Chen, SA Masino, J-M Vaugeois	45:385-412
Dual Specificity Protein Phosphatases: Therapeutic Targets for Cancer and Alzheimer's Disease	AP Ducruet, A Vogt, P Wipf, JS Lazo	45:725-50

AUTONOMIC NERVOUS SYSTEM

- Biochemical Mechanism of Nitroglycerin
Action and Tolerance: Is This Old
Mystery Solved?

H-L Fung 44:67-85

CARDIOVASCULAR SYSTEM

- K⁺ Channel Structure-Activity
Relationships and Mechanisms of
Drug-Induced QT Prolongation

CE Clancy, 43:441-61
J Kurokawa,
M Tateyama,
XHT Wehrens, RS Kass

- Novel Angiogenic Signaling Pathways and
Vascular Targets

R Bicknell, AL Harris 44:219-38

- Pleiotropic Effects of Statins

JK Liao, U Laufs 45:89-118

- Nitroxyl (HNO): Chemistry, Biochemistry,
and Pharmacology

JM Fukuto, CH Switzer, 45:335-55
KM Miranda,
DA Wink

- The Cardiac Fibroblast: Therapeutic Target
in Myocardial Remodeling and Failure

RD Brown, 45:657-87
SK Ambler,
MD Mitchell, CS Long

PULMONARY SYSTEM

- Cytokine Modulators as Novel Therapies
for Asthma

PJ Barnes 42:81-98

- Novel Pharmacological Approaches to
Manage Interstitial Lung Fibrosis in the
Twenty-First Century

SN Giri 43:73-95

Miscellaneous

TECHNIQUES

- Challenges for Biomedical Informatics and
Pharmacogenomics

RB Altman, TE Klein 42:113-33

ENVIRONMENTAL TOXICITY

- Challenging Dogma: Thresholds for
Genotoxic Carcinogens? The Case of
Vinyl Acetate

JG Hengstler, 43:485-520
MS Bogdanffy,
HM Bolt, F Oesch

- Neonicotinoid Insecticide Toxicology:
Mechanisms of Selective Action

M Tomizawa, 45:247-68
JE Casida

